The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials. Issue 3 (10th February 2019)

• Record Type: Journal Article
• Authors: Thalange, Nandu; Deeb, Larry; Klingensmith, Georgeanna; Franco, Denise R.; Bardtrum, Lars; Tutkunkardas, Deniz; Danne, Thomas
• Is Part Of: Pediatric diabetes. Volume 20:Issue 3(2019)
• Page Start: 314
• Page End: 320
• Publication Date: 2019-02-10
• Subjects: hyperglycemia -- insulin degludec/insulin aspart -- insulin detemir -- ketosis -- type 1 diabetes; Diabetes in children -- Periodicals; 616.462
• DOI: 10.1111/pedi.12821
• Languages: English
• ISSNs: 1399-543X

Abstract

Abstract : Background: Historically, data on the rate of hyperglycemia and ketosis have not been collected in clinical trials. However, it is clinically important to assess the rate of these events in children with type 1 diabetes (T1D). This question was addressed in two pediatric trials using insulin degludec (degludec). Objective: To assess the rate of hyperglycemia and ketosis in two‐phase 3b trials investigating degludec (Study 1) and degludec with insulin aspart (IDegAsp [Study 2]) vs insulin detemir (IDet). Subjects: Patients (aged 1‐17 years inclusive) with T1D treated with insulin for ≥3 months. Methods: Study 1: patients were randomized to degludec once daily (OD) or IDet OD/twice daily (BID) for 26 weeks, followed by a 26‐week extension phase. Study 2: patients were randomized to IDegAsp OD or IDet OD/BID for 16 weeks. Bolus mealtime IAsp was included in both studies. In Study 1, hyperglycemia was recorded if plasma glucose (PG) was >11.1 mmol/L, with ketone measurement required with significant hyperglycemia (>14.0 mmol/L). In Study 2, hyperglycemia was recorded with PG >14.0 mmol/L where the subject looked/felt ill, with ketone measurement also required in these hyperglycemic patients. In this post hoc analysis, the hyperglycemia threshold was 14.0 mmol/L for uniformity. Results: Despite similar rates of hyperglycemia with degludec/IDegAsp compared with IDet, the rates of ketosis were lower with degludec/IDegAsp. Conclusions: These trials, the first to systematically collect data on ketosis in pediatric patients with T1D, demonstrate the potential of degludec/IDegAsp to reduce rates of metabolic decompensation, compared with IDet.